EPRS
EPIRUS Biopharmaceuticals, IncNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Jul. 25, 12:04 PM
    | Mon, Jul. 25, 12:04 PM | 3 Comments
  • Tue, Jun. 14, 4:52 PM
    | Tue, Jun. 14, 4:52 PM | 3 Comments
  • Fri, May 20, 7:32 AM
    • Arrowhead Pharmaceuticals (NASDAQ:ARWR) initiated with Buy rating and $12 (140% upside) price target by Chardan Capital.
    • Amicus Therapeutics (NASDAQ:FOLD) initiated with Buy rating and $10 (45% upside) price target by Bank of America.
    • Quorum Health (NYSE:QHC) initiated with Equal Weight rating and $12 (2% upside) price target by Morgan Stanley.
    • TESARO (NASDAQ:TSRO) initiated with Outperform rating and $56 (30% upside) price target by Credit Suisse.
    • Prothena (NASDAQ:PRTA) initiated with Overweight rating and $60 (47% upside) price target by Barclays.
    • Mazor Robotics (NASDAQ:MZOR) upgraded to Outperform from Market Perform by Wells Fargo. Price target raised to $15-17 (14% upside from midpoint) from $10-13.
    • Eli Lilly (NYSE:LLY) upgraded to Strong Buy with a price target of $88.67 (19% upside) by the Vetr Community.
    • Haemonetics (NYSE:HAE) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $29 (5% upside) from $25.
    • Nanosphere (NASDAQ:NSPH) downgraded to Neutral from Buy by Rodman & Renshaw. Price target lowered to $1.35 (2% upside) from $2.00.
    • Anacor Pharmaceuticals (NASDAQ:ANAC) downgraded to Neutral from Buy by Mizuho Securities. Price target set at $99.25 (0% upside).
    • Globus Medical (NYSE:GMED) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $21 (10% downside risk) from $26.
    • EPIRUS Biopharmaceuticals (NASDAQ:EPRS) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $0.75 (27% upside).
    | Fri, May 20, 7:32 AM | 10 Comments
  • Fri, May 13, 11:51 AM
    • ConforMIS (CFMS -51%) downgraded to Neutral from Overweight by JP Morgan. Price target lowered to $8 (62% upside) from $18.
    • Johnson & Johnson (JNJ -0.5%) downgraded to Neutral from Buy by BTIG Research.
    • EPIRUS Biopharmaceuticals (EPRS +2.2%) downgraded to Neutral from Buy by BTIG Research.
    • BioDelivery Sciences (BDSI -1%) downgraded to Hold from Buy by Canto Fitzgerald. Price target lowered to $5 (150% upside) from $9.
    • NewLink Genetics (NLNK +7.6%) downgraded to Neutral from Buy by SunTrust Robinson Humphrey. Price target lowered to $12 (15% upside) from $59.
    • St. Jude Medical (STJ +0.3%) downgraded to Equal Weight from Overweight by Barclays. Price target raised to $80 (5% upside) from $74.
    • Zoetis (ZTS +0.3%) downgraded to Sell from Neutral by Goldman Sachs. Price target raised to $48 (4% upside) from $46.
    • Cogentix Medical (CGNT +9.1%) downgraded to Neutral from Buy by Roth Capital. Price target is $1.15 (25% upside).
    | Fri, May 13, 11:51 AM | 9 Comments
  • Wed, May 11, 12:49 PM
    | Wed, May 11, 12:49 PM | 2 Comments
  • Tue, May 10, 12:47 PM
    | Tue, May 10, 12:47 PM
  • Mon, May 9, 4:57 PM
    • Thinly traded nano cap EPIRUS Biopharmaceuticals (NASDAQ:EPRS) reprioritizes its pipeline, suspending development of lead product candidate BOW015, a biosimilar to J&J's (NYSE:JNJ) Remicade (infliximab), to focus on developing biosimilars for the treatment of rare diseases. For example, the company will allocate additional resources to advance BOW080, a biosimilar candidate to Alexion Pharmaceuticals' (NASDAQ:ALXN) Soliris (eculizumab), currently approved in the U.S. for the treatment of orphan diseases paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, and BOW070, a biosimilar candidate to Roche's (OTCQX:RHHBY) Actemra (tocilizumab) for the treatment of a rare lymphoproliferative disorder called Castleman's disease.
    • The company intends to rationalize the BOW015 program including possible partnerships, divestitures or other alternatives.
    • The reallocation of resources will include a workforce reduction of up to 40%. Concurrently, President & CEO Amit Munshi has stepped down, replaced by board member Scott Rocklage, Ph.D., former CEO of Cubist Pharmaceuticals.
    | Mon, May 9, 4:57 PM | 9 Comments
  • Tue, Mar. 15, 6:46 AM
    • EPIRUS Biopharmaceuticals (EPRS) Q4 results: Revenues: $0.3M; R&D Expense: $10.6M (+120.8%); SG&A: $5.8M (+7.4%); Operating Loss: ($16.1M) (-57.8%); Net Loss: ($15.4M) (-48.1%); Loss Per Share: ($0.63) (+21.3%).
    • FY2015 results: Revenues: $0.6M; R&D Expense: $31M (+90.2%); SG&A: $21.9M (-4.8%); Operating Loss: ($52.4M) (-33.3%); Net Loss: ($52.2M) (-24.9%); Loss Per Share: ($2.30) (+66.2%); Quick Assets: $31.5M.
    • No guidance given.
    | Tue, Mar. 15, 6:46 AM
  • Tue, Mar. 15, 6:03 AM
    • EPIRUS Biopharmaceuticals (NASDAQ:EPRS): Q4 EPS of -$0.63 misses by $0.07.
    • Revenue of $0.29M beats by $0.06M.
    | Tue, Mar. 15, 6:03 AM | 1 Comment
  • Tue, Feb. 9, 8:07 AM
    • EPIRUS Biopharmaceuticals (NASDAQ:EPRS) commences its pivotal Phase 3 clinical trial, called UNIFORM, to demonstrate the bioequivalence of BOW015 to J&J's (NYSE:JNJ) Remicade (infliximab) in rheumatoid arthritis (RA). The 58-week, double-blind, one-to-one randomized, comparator-controlled study will be conducted across sites in the U.S., Europe and Latin America. The primary endpoint is the proportion of patients achieving ACR20 (20% improvement in RA symptoms) at Week 16.
    • The company plans to file global marketing applications in 2017 based on 30-week data.
    | Tue, Feb. 9, 8:07 AM
  • Mon, Jan. 25, 12:41 PM
    | Mon, Jan. 25, 12:41 PM
  • Dec. 18, 2015, 12:46 PM
    | Dec. 18, 2015, 12:46 PM | 5 Comments
  • Dec. 16, 2015, 12:45 PM
    | Dec. 16, 2015, 12:45 PM
  • Nov. 16, 2015, 6:22 AM
    • EPIRUS Biopharmaceuticals (EPRS +5.9%) Q3 results: Revenues: $0.2M; R&D Expense: $9.2M (+70.4%); SG&A: $5.1M (-40.0%); Net Loss: ($14M) (-0.7%); Loss Per Share: ($0.59) (+53.9%); Quick Assets: $44.4M.
    • No guidance given.
    | Nov. 16, 2015, 6:22 AM
  • Nov. 16, 2015, 6:02 AM
    • EPIRUS Biopharmaceuticals (NASDAQ:EPRS): Q3 EPS of -$0.59 misses by $0.08.
    • Revenue of $0.22M misses by $0.28M.
    | Nov. 16, 2015, 6:02 AM
  • Nov. 10, 2015, 9:03 AM
    • EPIRUS Biopharmaceuticals (NASDAQ:EPRS) appoints Vincent Aurentz as Chief Business Officer. Previously, he was President of HemoShear Therapeutics where he oversaw scientific and business development activities.
    | Nov. 10, 2015, 9:03 AM